Literature DB >> 31732231

Pulmonary Hypertension Subtypes and Mortality in CKD.

Daniel L Edmonston1, Kishan S Parikh2, Sudarshan Rajagopal3, Linda K Shaw4, Dennis Abraham5, Alexander Grabner6, Matthew A Sparks7, Myles Wolf8.   

Abstract

RATIONALE &
OBJECTIVE: Pulmonary hypertension (PH) contributes to cardiovascular disease and mortality in patients with chronic kidney disease (CKD), but the pathophysiology is mostly unknown. This study sought to estimate the prevalence and consequences of PH subtypes in the setting of CKD. STUDY
DESIGN: Observational retrospective cohort study. SETTING & PARTICIPANTS: We examined 12,618 patients with a right heart catheterization in the Duke Databank for Cardiovascular Disease from January 1, 2000, to December 31, 2014. EXPOSURES: Baseline kidney function stratified by CKD glomerular filtration rate category and PH subtype. OUTCOMES: All-cause mortality. ANALYTICAL APPROACH: Multivariable Cox proportional hazards analysis.
RESULTS: In this cohort, 73.4% of patients with CKD had PH, compared with 56.9% of patients without CKD. Isolated postcapillary PH (39.0%) and combined pre- and postcapillary PH (38.3%) were the most common PH subtypes in CKD. Conversely, precapillary PH was the most common subtype in the non-CKD cohort (35.9%). The relationships between mean pulmonary artery pressure, pulmonary capillary wedge pressure, and right atrial pressure with mortality were similar in both the CKD and non-CKD cohorts. Compared with those without PH, precapillary PH conferred the highest mortality risk among patients without CKD (HR, 2.27; 95% CI, 2.00-2.57). By contrast, in those with CKD, combined pre- and postcapillary PH was associated with the highest risk for mortality in CKD in adjusted analyses (compared with no PH, HRs of 1.89 [95% CI, 1.57-2.28], 1.87 [95% CI, 1.52-2.31], 2.13 [95% CI, 1.52-2.97], and 1.63 [95% CI, 1.12-2.36] for glomerular filtration rate categories G3a, G3b, G4, and G5/G5D). LIMITATIONS: The cohort referred for right heart catheterization may not be generalizable to the general population. Serum creatinine data in the 6 months preceding catheterization may not reflect true baseline CKD. Observational design precludes assumptions of causality.
CONCLUSIONS: In patients with CKD referred for right heart catheterization, PH is common and associated with poor survival. Combined pre- and postcapillary PH was common and portended the worst survival for patients with CKD. Published by Elsevier Inc.

Entities:  

Keywords:  PH subtype; Pulmonary hypertension (PH); cardiovascular complication; chronic kidney disease (CKD); combined pre- and post-capillary PH; diagnostic catheterization; end-stage renal disease (ESRD); heart failure; hemodialysis; mortality; pulmonary capillary wedge pressure; pulmonary disease

Mesh:

Year:  2019        PMID: 31732231      PMCID: PMC7183902          DOI: 10.1053/j.ajkd.2019.08.027

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  45 in total

1.  Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension.

Authors:  Precious P Landburg; Tom Teerlink; Eduard J van Beers; Frits A J Muskiet; Mies C Kappers-Klunne; Joost W J van Esser; Melvin R Mac Gillavry; Bart J Biemond; Dees P M Brandjes; Ashley J Duits; John-John Schnog
Journal:  Haematologica       Date:  2008-07-18       Impact factor: 9.941

2.  Elevated homocysteine and asymmetric dimethyl arginine levels in pulmonary hypertension associated with congenital heart disease.

Authors:  Cihat Sanli; Deniz Oguz; Rana Olgunturk; Fatma Sedef Tunaoglu; Serdar Kula; Hatice Pasaoglu; Ozlem Gulbahar; Ayhan Cevik
Journal:  Pediatr Cardiol       Date:  2012-04-21       Impact factor: 1.655

3.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

4.  Presence and outcomes of kidney disease in patients with pulmonary hypertension.

Authors:  Sankar D Navaneethan; Edgard Wehbe; Gustavo A Heresi; Varun Gaur; Omar A Minai; Susana Arrigain; Joseph V Nally; Jesse D Schold; Mahboob Rahman; Raed A Dweik
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

5.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

6.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.

Authors:  P Vallance; A Leone; A Calver; J Collier; S Moncada
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

7.  Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure.

Authors:  Miki Imazu; Hiroyuki Takahama; Makoto Amaki; Yasuo Sugano; Takahiro Ohara; Takuya Hasegawa; Hideaki Kanzaki; Toshihisa Anzai; Naoki Mochizuki; Hiroshi Asanuma; Masanori Asakura; Masafumi Kitakaze
Journal:  Hypertens Res       Date:  2016-09-29       Impact factor: 3.872

8.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.

Authors:  M Humbert; G Monti; F Brenot; O Sitbon; A Portier; L Grangeot-Keros; P Duroux; P Galanaud; G Simonneau; D Emilie
Journal:  Am J Respir Crit Care Med       Date:  1995-05       Impact factor: 21.405

9.  Renal thrombotic microangiopathy and pulmonary arterial hypertension in a patient with late-onset cobalamin C deficiency.

Authors:  Taylor E Petropoulos; Maria Erika Ramirez; John Granton; Christoph Licht; Rohan John; Yasbanoo Moayedi; Chantal F Morel; Rory F McQuillan
Journal:  Clin Kidney J       Date:  2017-10-26

10.  Epidemiology and risk factors in CKD patients with pulmonary hypertension: a retrospective study.

Authors:  Qian Zhang; Le Wang; Hongbing Zeng; Yongman Lv; Yi Huang
Journal:  BMC Nephrol       Date:  2018-03-20       Impact factor: 2.388

View more
  4 in total

1.  Echocardiography to Screen for Pulmonary Hypertension in CKD.

Authors:  Daniel L Edmonston; Sudarshan Rajagopal; Myles Wolf
Journal:  Kidney Int Rep       Date:  2020-10-03

Review 2.  Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.

Authors:  Carl P Walther; Vijay Nambi; Nicola A Hanania; Sankar D Navaneethan
Journal:  Am J Kidney Dis       Date:  2020-03-19       Impact factor: 8.860

3.  Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension.

Authors:  Sankar D Navaneethan; Carl P Walther; L Parker Gregg; Shweta Bansal; Wolfgang C Winkelmayer; Vijay Nambi; Jingbo Niu
Journal:  Am J Kidney Dis       Date:  2021-04-24       Impact factor: 8.860

4.  Beneficial Effects of Pulmonary Vasodilators on Pre-Capillary Pulmonary Hypertension in Patients with Chronic Kidney Disease on Hemodialysis.

Authors:  Keiji Kimuro; Kazuya Hosokawa; Kohtaro Abe; Kohei Masaki; Satomi Imakiire; Takafumi Sakamoto; Hiroyuki Tsutsui
Journal:  Life (Basel)       Date:  2022-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.